Singapore, April 9 -- Australia-based Lumonus, the company behind Lumonus AI, a platform for radiation oncology clinical workflow and automated treatment planning, has announced a collaboration with US-based Memorial Sloan Kettering Cancer Center (MSK), one of the world's premier cancer centres and a leader in radiation therapy treatment planning research.

Through this relationship, Lumonus will license and co-develop MSK's ECHO mathematical optimisation engine into the Lumonus platform and will invest in joint research focused on advancing automated radiation therapy treatment planning.

MSK's ECHO optimisation engine uses constraint-based mathematical methods to compute radiation therapy treatment plans from first principles. Developed...